Propel's Biotech Portfolio Shifts
Propel Bio Management Boosts Healthcare Holdings, Adding Kyverna Stake and Increasing Phathom
Propel Bio Management LLC reported multiple changes to its healthcare stock holdings in recent SEC filings, including a new position in Kyverna Therapeutics (KYTX) worth about $6.3 million and a stake increase in Compass Pathways (CMPS) that brought its value to roughly $5.9 million. The firm also increased its exposure to Nektar Therapeutics (NKTR) to about $3.5 million and boosted its position in Phathom Pharmaceuticals (PHAT) to approximately $12.3 million, where it became one of the fund’s largest holdings. Propel’s largest portfolio weight highlighted in these updates was Phathom at about 10.5%, while Kyverna, Compass Pathways, and Nektar were each described as meaningful mid-to-lower tier positions within the portfolio. In addition, Propel initiated a new investment in SAB Biotherapeutics (SABS) valued at about $2.4 million. Across these companies, the filings also show broad participation by other institutional investors, with overall institutional ownership ranging from a minority stake to near-total ownership depending on the company.
Key Points
For Kyverna Therapeutics (KYTX), Propel’s new stake came via an acquisition of 666,666 shares in the 4th quarter, and the fund held about 1.52% of KYTX at quarter-end; other institutional activity included Bank of America Corp. DE boosting its KYTX position by 41.6% (to 21,788 shares).
For Compass Pathways (CMPS), Propel reported owning 861,778 shares after adding 351,778 in the 4th quarter; among other investors, Raymond James Financial Inc. increased its holding by 82.7% (to 13,763 shares), and the article notes institutional investors own 46.19% of CMPS.
For Nektar Therapeutics (NKTR), the article adds insider activity: CEO Howard W. Robin sold 444 shares on May 19 at an average price of $65.51 (totaling $29,086.44). Propel also increased its position to 82,822 shares (about 0.41% ownership).
For Phathom Pharmaceuticals (PHAT), institutional concentration is very high: the article states institutional investors own 99.01% of PHAT. It also highlights other sizable moves, including Jones Financial Companies LLC increasing its PHAT stake by 442.6% (to 2,523 shares).
For SAB Biotherapeutics (SABS), the article provides additional balance-sheet context (debt-to-equity of 0.01 and quick/current ratios of 11.45) and notes other investor momentum: Goldman Sachs Group Inc. raised its position by 357.6% (to 51,348 shares worth $192,000).
Sentiment
Mostly PositivePublishers
10
Articles
0
Reach
10
